Style | Citing Format |
---|---|
MLA | Rahimi Hajiabadi H, et al.. "Disseminated Bacille Calmette-Guerin Vaccine-Induced Disease in a Sample of Iranian Children: A Longitudinal Case-Series Study." Archives of Pediatric Infectious Diseases, vol. 13, no. 2, 2025, pp. -. |
APA | Rahimi Hajiabadi H, Kiani G, Esfahani SNM, Emadoleslami MS, Momen T, Pourmoghaddas Z (2025). Disseminated Bacille Calmette-Guerin Vaccine-Induced Disease in a Sample of Iranian Children: A Longitudinal Case-Series Study. Archives of Pediatric Infectious Diseases, 13(2), -. |
Chicago | Rahimi Hajiabadi H, Kiani G, Esfahani SNM, Emadoleslami MS, Momen T, Pourmoghaddas Z. "Disseminated Bacille Calmette-Guerin Vaccine-Induced Disease in a Sample of Iranian Children: A Longitudinal Case-Series Study." Archives of Pediatric Infectious Diseases 13, no. 2 (2025): -. |
Harvard | Rahimi Hajiabadi H et al. (2025) 'Disseminated Bacille Calmette-Guerin Vaccine-Induced Disease in a Sample of Iranian Children: A Longitudinal Case-Series Study', Archives of Pediatric Infectious Diseases, 13(2), pp. -. |
Vancouver | Rahimi Hajiabadi H, Kiani G, Esfahani SNM, Emadoleslami MS, Momen T, Pourmoghaddas Z. Disseminated Bacille Calmette-Guerin Vaccine-Induced Disease in a Sample of Iranian Children: A Longitudinal Case-Series Study. Archives of Pediatric Infectious Diseases. 2025;13(2):-. |
BibTex | @article{ author = {Rahimi Hajiabadi H and Kiani G and Esfahani SNM and Emadoleslami MS and Momen T and Pourmoghaddas Z}, title = {Disseminated Bacille Calmette-Guerin Vaccine-Induced Disease in a Sample of Iranian Children: A Longitudinal Case-Series Study}, journal = {Archives of Pediatric Infectious Diseases}, volume = {13}, number = {2}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Rahimi Hajiabadi H AU - Kiani G AU - Esfahani SNM AU - Emadoleslami MS AU - Momen T AU - Pourmoghaddas Z TI - Disseminated Bacille Calmette-Guerin Vaccine-Induced Disease in a Sample of Iranian Children: A Longitudinal Case-Series Study JO - Archives of Pediatric Infectious Diseases VL - 13 IS - 2 SP - EP - PY - 2025 ER - |